CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

An Oregon veteran's 16-year fight with the VA over benefits for inclusion body myositis, or IBM, is part of a growing ...

Inclusion body myositis (IBM) is a slowly progressive muscle-wasting disease that typically starts with weakness in the hands and upper legs and often leads to difficulty swallowing. There is no cure, ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results ...

This Morning presenter Ben Shephard shared his encouragement to a colleague who spoke openly about his MND diagnosis on the ...

The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the ...

Scientists sum up the evidence—or lack thereof—for the most popular peptides hyped for athletic performance and recovery.

This Morning presenters Ben Shephard and Cat Deeley were left emotional as former ITV commissioner Matt Cox joined them on ...

The All-American Breakfast is your standard bearer, your baseline, your “this is what breakfast should be” meal that includes ...

In a new research report, a team of scientists led by Johns Hopkins Medicine say people with severe obesity and a common type ...

This quote by Swami Vivekananda teaches that success is not about doing many things, but about doing one thing with full ...